Research Argenx heads to FDA with Vyvgart after ph. 3 win in potential blockbuster autoimmune indicationBy Healthcare Propulsion StaffAugust 17, 20260 With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap. On Monday,…
Research Neurocrine stands by blockbuster hopeful Vykat XR as Prader-Willi docs raise potential safety flagsBy Healthcare Propulsion StaffAugust 13, 20260 Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to…
